Larazotide
Larazotide acetate · AT-1001 · INN-202
Last reviewed:
- MW
- 726.84 Da
- Sequence
- GGVLVQPG
- Research focus
- gut healing
An eight-amino-acid synthetic peptide investigated as a tight-junction modulator and zonulin antagonist for coeliac disease and intestinal-barrier research.
Mechanism of action
Larazotide is proposed to antagonise zonulin signalling at intestinal tight junctions, reducing paracellular permeability of the gut epithelium. Animal models report decreased macromolecular flux across the intestinal barrier and reduced downstream activation of mucosal immune responses.
Research history
Discovered through work on zonulin (the eukaryotic homologue of Vibrio cholerae zonula occludens toxin) by Alessio Fasano's group. Progressed through Phase III investigation in coeliac disease as a non-dietary adjunct to a gluten-free diet.
Summarised studies
Larazotide reduces persistent coeliac symptoms (Phase IIb)
Leffler D.A. et al., Gastroenterology · 2015
In coeliac patients with persistent symptoms despite a gluten-free diet, oral larazotide 0.5 mg three times daily significantly reduced symptom severity compared with placebo.
Larazotide in intestinal permeability
Paterson B.M. et al., Aliment Pharmacol Ther · 2007
Oral larazotide reduced gluten-induced increases in intestinal permeability (as measured by lactulose/mannitol ratio) versus placebo in coeliac patients.
Safety profile
Larazotide acetate has been generally well tolerated in coeliac trials, with adverse events typically limited to mild gastrointestinal symptoms. Its narrow site of action (luminal tight junctions, minimal systemic absorption) underlies its favourable safety profile.
UK regulatory status
Larazotide is not licensed for any indication in the UK. Clinical development for coeliac disease has continued internationally but has not produced UK marketing authorisation. Research-laboratory possession is unrestricted.
Frequently asked questions
What is zonulin?
Is larazotide systemically absorbed?
Where to source Larazotide for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.
Appears in research stacks
Cited in research summaries
Related peptides
KPV
A three-amino-acid C-terminal fragment of α-MSH studied for its anti-inflammatory effects in colitis, atopic skin conditions, and mucosal healing models — without the pigmentary effects of full-length MSH.
BPC-157
A 15-amino-acid pentadecapeptide derived from a protective protein found in human gastric juice. The most-studied healing research peptide, with extensive pre-clinical work on tendon, ligament, gut, and vascular repair.
LL-37
The only human cathelicidin antimicrobial peptide — a 37-residue cationic helix studied for direct antimicrobial action, wound healing, angiogenesis, and modulation of host immune responses.